GNCA GENOCEA BIOSCIENCES

Genocea Biosciences to Host Investor Webinar

Genocea Biosciences to Host Investor Webinar

CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced details for a planned investor webinar to coincide with the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13. The presentation, beginning at 4:30 PM EDT on Friday, April 8th will be followed by a Q&A session. The Genocea team will discuss , including late-breaking data from the TiTAN™ clinical trial for the neoantigen-targeted peripheral T cell therapy product candidate GEN-011, and results demonstrating successful production of GEN-011 using Genocea’s PLANET™ manufacturing process.

Featured speakers include:

  • Melissa Johnson, MD, Medical Oncologist at Sarah Cannon Research Institute at Tennessee Oncology
  • Chip Clark, President & Chief Executive Officer, Genocea Biosciences
  • Tom Davis, MD, Chief Medical Officer, Genocea Biosciences
  • Jessica Flechtner, PhD, Chief Scientific Officer, Genocea Biosciences
  • Ray Stapleton, PhD, Chief Technology Officer, Genocea Biosciences

Attendees can register for the event. Access to the webcast will be available on the investor relations section of Genocea’s website, including an archived replay of the webcast at .

About GEN-011

GEN-011 is a neoantigen-targeted peripherally derived T cell therapy candidate comprised of autologous CD4+ and CD8+ T cells that are specific for up to 30 ATLAS-identified neoantigens to limit tumor escape. NPTs have minimal bystander, non-tumor-specific cells, and are devoid of Inhibigen-specific cells which may be detrimental to clinical response.

About the GEN-011 TiTAN clinical trial

TiTAN is an open-label, multi-center Phase1/2a trial evaluating safety, tolerability, T cell persistence and proliferation and clinical efficacy. The TiTAN clinical trial is testing two dosing regimens, a repeated fractional dose regimen of GEN-011 without lymphodepletion and a single dose administration of GEN-011 after lymphodepletion. Both groups will receive interleukin-2 after GEN-011 dosing to maximize the tumor-killing potential of the infused cells.

About Genocea Biosciences, Inc.

Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform can comprehensively profile each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, Inhibigens™, that drive pro-tumor immune responses. We have two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our adoptive T cell therapy comprising neoantigen-targeted peripheral cells for which we are conducting a Phase 1/2a clinical trial. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases. To learn more, please visit .

Investor Contact:

Dan Ferry

617-430-7576

 Media Contact:

Sarah O’Connell

 





EN
04/04/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GENOCEA BIOSCIENCES

 PRESS RELEASE

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

Genocea Announces Wind Down of Operations and Delisting From NASDAQ CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its Board of Directors voted to wind down the Company’s ongoing operations and terminate the Company’s remaining employees except those deemed necessary to complete an orderly wind down. On May 23, 2022, the Company delivered formal notice to The Nasdaq Stock Market, Inc. of its intent to voluntarily delist its Common Stock from the ...

 PRESS RELEASE

Genocea Initiates Restructuring and Announces Plan to Explore Strategi...

Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and has engaged professional advisors, including an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of the Company,...

 PRESS RELEASE

Genocea Biosciences to Host Investor Webinar

Genocea Biosciences to Host Investor Webinar CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced details for a planned investor webinar to coincide with the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13. The presentation, beginning at 4:30 PM EDT on Friday, April 8th will be followed by a Q&A session. The Genocea team will discuss , including late-breaking data from the TiTAN™ clinical trial for the neoantigen-targeted peripher...

 PRESS RELEASE

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conferenc...

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17th at 8:40 A.M. ET. A live webcast of the presentation will be available under the "Events and Presentations" tab of the investor relations section of the Genocea website at . A replay of t...

 PRESS RELEASE

Genocea Provides Fourth Quarter 2021 Corporate Update

Genocea Provides Fourth Quarter 2021 Corporate Update Initial GEN-011 clinical trial data to be presented at AACR Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the fourth quarter ended December 31, 2021. GEN-011 TiTAN™ trial update Genocea is conducting the Phase I/2a TiTAN clinical trial for its lead program GEN-011, a neoantigen-targeted peripheral T cell (NPT) therapy ca...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch